Tumour-informed liquid biopsies to monitor advanced melanoma patients under immune checkpoint inhibition
Christopher Schroeder, Andrea Forschner(University Children's Hospital Tübingen), Jakob Admard(University of Tübingen), Olga Kelemen(University of Tübingen), Irina Bonzheim(University Children's Hospital Tübingen), Brigitte Gückel(University Children's Hospital Tübingen), Francesc Muyas(European Bioinformatics Institute), Sorin Armeanu–Ebinger(University Children's Hospital Tübingen), Thomas Küstner(University of Tübingen), Peter Martus(University of Tübingen), Sergios Gatidis(University of Tübingen), Christina Pfannenberg(University Children's Hospital Tübingen), Lukas Flatz(University of Zurich), Claus Garbe(University Children's Hospital Tübingen), Stephan Ossowski(Max Planck Institute for Developmental Biology), Leon Schütz(University of Tübingen)
Cited by 19
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
|The Lancet Oncology|2014|978
Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines
|European Journal of Cancer|2019|589
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
|The Oncologist|2011|579